Royalty Pharma bets an extra half billion on MS candidate

Royalty Pharma has acquired more rights to Biogen’s multiple sclerosis treatment, dimethyl fumarate (Tecfidera).

Royalty announced a payment of 510 million US dollars for the indirect interest in the drug’s sales, paying for the earn-out with cash to former shareholders of Fumapharm AG.

It follows similar payments in May 2012, of 761 million dollars, Royalty said in a statement.

“The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec’s Tecfidera (dimethyl fumarate), an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis.
“The earn-out also includes an indirect interest in sales of Fumaderm, a therapeutic approved in Germany for the treatment of moderate to severe plaque psoriasis.”
Alexander v. Perfall, vice-president, investor relations and public affairs, Royalty Pharma.





Related news:

Royalty Pharma acquires additional interest in Tecfidera for $510 million (The Pharma Letter).

Royalty Pharma buys bigger Tecfidera interest (PMLiVE).

Royalty Pharma acquires interest in Biogen drug (The Wall Street Journal).

Reference links:

Royalty Pharma announces acquisition of an additional interest to the former shareholders of Fumapharm AG (Royalty press release).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.